While this editing efficiency is at the low end of the therapeutic range, application of this delivery approach in human CF airway epithelia with the R553X mutation achieved similar levels of editing and conferred partial restoration of CFTR function. The gene discussed is CFTR; the disease is cystic fibrosis.